BPC-157 is a peptide composed of 15 amino acids with potential protective properties
(If youre taking extended-release DHB formulations, they can be taken once daily, with or without food.) Listen to your own body, and if youre experiencing any stomach upset, try adjusting your timing
Serious side effects are also slightly more common on tirzepatide
Discontinued GLP-1 agonists: 1
Retatrutide did not just match these benchmarks
The challenge for the next few years is making sure patients are able to access them. In their latest analysis, Tsai and his colleagues found that among the commercially insured, less than 1% of people with obesity were being treated with either surgery or GLP-1 drugs, underscoring that despite the shifts underway, obesity remains a profoundly underaddressed public health issue